XOMA is the latest in a long line of companies forced to relinquish development programmes in order to save money. The company has restructured its 2004 agreement with Novartis into a fully funded collaboration with an immediate cash payment and debt reduction, as well as suspending a number of its development programmes. XOMA plans to focus its resources on its diabetes product, XOMA 052.